Ashokkumar Chethan, Ningappa Mylarappa, Raghu Vikram, Mazariegos George, Higgs Brandon W, Morgan Paul, Remaley Lisa, Fazzolare Martin Tamara, Holzer Pamela, Trostle Kevin, Xu Qingyong, Zeevi Adriana, Squires James, Soltys Kyle, Horslen Simon, Khanna Ajai, Ganoza Armando, Sindhi Rakesh
Department of Surgery, Hillman Center for Pediatric Transplantation, UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh, PA.
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, UPMC Children's Hospital Pittsburgh, PA.
Transplant Direct. 2024 Feb 26;10(3):e1589. doi: 10.1097/TXD.0000000000001589. eCollection 2024 Mar.
Enhanced B-cell presentation of donor alloantigen relative to presentation of HLA-mismatched reference alloantigen is associated with acute cellular rejection (ACR), when expressed as a ratio called the antigen presenting index (API) in an exploratory cohort of liver and intestine transplant (LT and IT) recipients.
To test clinical performance, we measured the API using the previously described 6-h assay in 84 LT and 54 IT recipients with median age 3.3 y (0.05-23.96). Recipients experiencing ACR within 60 d after testing were termed rejectors.
We first confirmed that B-cell uptake and presentation of alloantigen induced and thus reflected the alloresponse of T-helper cells, which were incubated without and with cytochalasin and primaquine to inhibit antigen uptake and presentation, respectively. Transplant recipients included 76 males and 62 females. Rejectors were tested at median 3.6 d before diagnosis. The API was higher among rejectors compared with nonrejectors (2.2 ± 0.2 versus 0.6 ± 0.04, value = 1.7E-09). In logistic regression and receiver-operating-characteristic analysis, API ≥1.1 achieved sensitivity, specificity, and positive and negative predictive values for predicting ACR in 99 training set samples. Corresponding metrics ranged from 80% to 88% in 32 independent posttransplant samples, and 73% to 100% in 20 independent pretransplant samples. In time-to-event analysis, API ≥1.1 predicted higher incidence of late donor-specific anti-HLA antibodies after API measurements in LT recipients ( = 0.011) and graft loss in IT recipients ( = 0.008), compared with recipients with API <1.1, respectively.
Enhanced donor antigen presentation by circulating B cells predicts rejection after liver or intestine transplantation as well as higher incidence of DSA and graft loss late after transplantation.
在肝移植和肠移植(LT和IT)受者的探索性队列中,当以称为抗原呈递指数(API)的比率表示时,与HLA错配参考同种异体抗原呈递相比,供体同种异体抗原的B细胞呈递增强与急性细胞排斥反应(ACR)相关。
为了测试临床性能,我们使用先前描述的6小时检测方法在84例LT受者和54例IT受者中测量了API,这些受者的中位年龄为3.3岁(0.05 - 23.96岁)。在检测后60天内发生ACR的受者被称为排斥者。
我们首先证实,同种异体抗原的B细胞摄取和呈递诱导并因此反映了辅助性T细胞的同种异体反应,分别在不使用细胞松弛素和使用伯氨喹的情况下孵育以抑制抗原摄取和呈递。移植受者包括76名男性和62名女性。排斥者在诊断前中位3.6天接受检测。与非排斥者相比,排斥者的API更高(2.2 ± 0.2对0.6 ± 0.04,P值 = 1.7E - 09)。在逻辑回归和受试者工作特征分析中,API≥1.1在99个训练集样本中实现了预测ACR的敏感性、特异性以及阳性和阴性预测值。在32个独立的移植后样本中,相应指标范围为80%至88%,在20个独立的移植前样本中为73%至100%。在生存时间分析中,与API < 1.1的受者相比,API≥1.1预测LT受者在API测量后晚期供体特异性抗HLA抗体的发生率更高(P = 0.011),以及IT受者的移植物丢失发生率更高(P = 0.008)。
循环B细胞增强的供体抗原呈递可预测肝或肠移植后的排斥反应以及移植后期DSA的更高发生率和移植物丢失。